Informa Life Sciences is part of the Knowledge and Networking Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.
Group Leader and Postdoc, Therapeutic and Diagnostic Antibodies at University of Leuven
Dr. Kevin Hollevoet has a degree in Bioengineering (2008, Ghent University, Belgium), a PhD in Medical Sciences (2011, Ghent University), and a postgraduate in Innovation and Entrepreneurship (2017, University of Leuven, Belgium). During his PhD, he managed a multi-center clinical trial that provided lasting insights on the application of several blood protein markers in the clinical management of mesothelioma. Dr. Hollevoet subsequently joined the NCI (Bethesda, MD) for a two-year postdoc on immunotoxins (antibody-toxin conjugates). His pre-clinical findings on anti-mesothelin immunotoxins in pancreatic cancer were pivotal in initiating clinical trials. In 2013, Dr. Hollevoet joined the University of Leuven (KU Leuven), where he currently heads the Antibody Gene Transfer Program at the Laboratory for Therapeutic and Diagnostic Antibodies. This research branch is fully dedicated to advancing nucleotide-based antibody therapy in different disease areas, including (immuno-)oncology, infectious diseases and CNS. Antibody gene transfer seeks to administer to patients the antibody-encoding nucleotides, rather than the antibody protein, allowing the body itself to produce the therapeutic.